抗病毒药物用于流感暴露后预防:系统评价与网络Meta分析
该系统评价与网络Meta分析纳入33项随机对照试验、共19096人,评估6种抗病毒药物暴露后预防流感的效果。扎那米韦、奥司他韦、拉尼娜米韦和巴洛沙韦可能对重症高危人群的症状性季节性流感有重要降低作用,但对低危人群可能无重要降低作用。
要点
- 扎那米韦、奥司他韦、拉尼娜米韦和巴洛沙韦可能降低重症高危人群暴露后症状性季节性流感风险。
- 上述四种药物对低危人群暴露后症状性季节性流感可能无重要降低作用。
- 奥司他韦、拉尼娜米韦、巴洛沙韦和金刚烷胺可能降低全部流感(症状性及无症状感染)风险。
核心结论
- 暴露后预防使用扎那米韦、奥司他韦、拉尼娜米韦或巴洛沙韦可能降低重症高危人群接触季节性流感病毒后发生症状性季节性流感的风险。
- 暴露后预防使用扎那米韦、奥司他韦、拉尼娜米韦或巴洛沙韦可能降低接触与人类感染重症相关的新型甲型流感病毒后发生症状性人畜共患流感的风险。
研究设计与样本
- 为支持世界卫生组织流感指南更新,开展系统评价与网络Meta分析。
- 系统检索MEDLINE、Embase、Cochrane对照试验中心注册库、护理与联合健康文献累积索引、Global Health、Epistemonikos和ClinicalTrials.gov,检索截至2023年9月20日发表的随机对照试验。
- 纳入33项试验、6种抗病毒药物(扎那米韦、奥司他韦、拉尼娜米韦、巴洛沙韦、金刚烷胺和金刚乙胺),共19096人(平均年龄6.75至81.15岁)。
- 采用频率学随机效应模型进行网络Meta分析,并使用GRADE方法评估证据确定性。
- 研究注册于PROSPERO,注册号CRD42023466450。
主要发现
- 在重症高危人群中及时给药(如暴露后48小时内)后,扎那米韦(风险比0.35,95%CI 0.25-0.50)、奥司他韦(0.40,0.26-0.62)、拉尼娜米韦(0.43,0.30-0.63)和巴洛沙韦(0.43,0.23-0.79)可能对症状性季节性流感有重要降低作用(中等确定性)。
- 在重症低危人群中及时给药后,上述抗病毒药物可能对症状性季节性流感无重要降低作用(中等确定性)。
- 在接触与人类感染重症相关的新型甲型流感病毒的人群中及时给药后,扎那米韦、奥司他韦、拉尼娜米韦和巴洛沙韦可能对症状性人畜共患流感有重要降低作用(低确定性)。
- 奥司他韦、拉尼娜米韦、巴洛沙韦和金刚烷胺可能降低全部流感(症状性和无症状感染)风险(中等确定性)。
- 扎那米韦、奥司他韦、拉尼娜米韦和巴洛沙韦对预防无症状流感病毒感染或全因死亡可能几乎没有或没有作用(高或中等确定性);奥司他韦对住院可能几乎没有或没有作用(中等确定性)。
关键数值与推荐
- 扎那米韦风险比0.35(95%CI 0.25-0.50),奥司他韦0.40(0.26-0.62),拉尼娜米韦0.43(0.30-0.63),巴洛沙韦0.43(0.23-0.79),均为重症高危人群及时暴露后预防的症状性季节性流感结果(中等确定性)。
- 全部6种抗病毒药物均未显著增加药物相关不良事件或严重不良事件的发生率,但证据确定性不一。
临床怎么用
- 对于重症高危人群接触季节性流感病毒后,可考虑及时(如48小时内)使用扎那米韦、奥司他韦、拉尼娜米韦或巴洛沙韦进行暴露后预防。
- 对于重症低危人群,上述药物及时暴露后预防可能对症状性季节性流感无重要降低作用。
- 对于接触与人类感染重症相关的新型甲型流感病毒的人群,可考虑及时使用扎那米韦、奥司他韦、拉尼娜米韦或巴洛沙韦进行暴露后预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiviral post-exposure prophylaxis with neuraminidase inhibitors can reduce the incidence of influenza and the risk of symptomatic influenza, but the efficacy of the other classes of antiviral remains unclear. To support an update of WHO influenza guidelines, this systematic review and network meta-analysis evaluated antiviral drugs for post-exposure prophylaxis of influenza. METHODS: We systematically searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, Global Health, Epistemonikos, and ClinicalTrials.gov for randomised controlled trials published up to Sept 20, 2023 that evaluated the efficacy and safety of antivirals compared with another antiviral or placebo or standard care for prevention of influenza. Pairs of reviewers independently screened studies, extracted data, and assessed the risk of bias. We performed network meta-analyses with frequentist random effects model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. The outcomes of interest were symptomatic or asymptomatic infection, admission to hospital, all-cause mortality, adverse events related to antivirals, and serious adverse events. This study is registered with PROSPERO, CRD42023466450. FINDINGS: Of 11 845 records identified by our search, 33 trials of six antivirals (zanamivir, oseltamivir, laninamivir, baloxavir, amantadine, and rimantadine) that enrolled 19 096 individuals (mean age 6·75-81·15 years) were included in this systematic review and network meta-analysis. Most of the studies were rated as having a low risk of bias. Zanamivir, oseltamivir, laninamivir, and baloxavir probably achieve important reductions in symptomatic influenza in individuals at high risk of severe disease (zanamivir: risk ratio 0·35, 95% CI 0·25-0·50; oseltamivir: 0·40, 0·26-0·62; laninamivir: 0·43, 0·30-0·63; baloxavir: 0·43, 0·23-0·79; moderate certainty) when given promptly (eg, within 48 h) after exposure to seasonal influenza. These antivirals probably do not achieve important reductions in symptomatic influenza in individuals at low risk of severe disease when given promptly after exposure to seasonal influenza (moderate certainty). Zanamivir, oseltamivir, laninamivir, and baloxavir might achieve important reductions in symptomatic zoonotic influenza in individuals exposed to novel influenza A viruses associated with severe disease in infected humans when given promptly after exposure (low certainty). Oseltamivir, laninamivir, baloxavir, and amantadine probably decrease the risk of all influenza (symptomatic and asymptomatic infection; moderate certainty). Zanamivir, oseltamivir, laninamivir, and baloxavir probably have little or no effect on prevention of asymptomatic influenza virus infection or all-cause mortality (high or moderate certainty). Oseltamivir probably has little or no effect on admission to hospital (moderate certainty). All six antivirals do not significantly increase the incidence of drug-related adverse events or serious adverse events, although the certainty of evidence varies. INTERPRETATION: Post-exposure prophylaxis with zanamivir, oseltamivir, laninamivir, or baloxavir probably decreases the risk of symptomatic seasonal influenza in individuals at high risk for severe disease after exposure to seasonal influenza viruses. Post-exposure prophylaxis with zanamivir, oseltamivir, laninamivir, or baloxavir might reduce the risk of symptomatic zoonotic influenza after exposure to novel influenza A viruses associated with severe disease in infected humans. FUNDING: World Health Organization.
引用
- Zhao Y, Gao Y, Guyatt G, et al. Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis. Lancet. 2024. PMID: 39181596. doi:10.1016/S0140-6736(24)01357-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。